Clinical trial · no report yet · Phase 3
CodeBreak 300
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
- NCT05198934 ↗
- Completed
- Amgen
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 54 | |
| YouTube | 35 | |
| Podcasts | 28 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Colorectal Cancer (CRC)
- Interventions
- Sotorasib; Panitumumab; Trifluridine and Tipiracil; Regorafenib
- Arms
- Arm A: Sotorasib 960 mg QD + panitumumab · Experimental
- Arm B: Sotorasib 240 mg QD + panitumumab · Experimental
- Arm C : Investigator's choice · Active comparator
- Enrollment
- 160
- Primary outcomes
- Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by BICR
- Sponsor
- Amgen
- Start
- Apr 19, 2022
- Primary completion
- Jul 16, 2025
- Results posted
- Yes
- Registry record
- NCT05198934 · updated Jul 22, 2026
Publications
linked from the registry- Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Chan E, Chao J, Saportas Y, Tran Q, Cremolini C, Pietrantonio F. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023 Dec 7;389(23):2125-2139. doi: 10.1056/NEJMoa2308795. Epub 2023 Oct 22. PubMed 37870968
- Pietrantonio F, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Chan E, Chao J, Tran Q, Cremolini C, Fakih M. Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. J Clin Oncol. 2025 Jul;43(19):2147-2154. doi: 10.1200/JCO-24-02026. Epub 2025 Apr 11. PubMed 40215429
- Modest DP, Fakih M, Salvatore L, Esaki T, Lopez-Bravo DP, Taieb J, Karamouzis M, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Cremolini C, Tran Q, Chan E, Chao J, Majer IM, Pietrantonio F. Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial. Lancet Oncol. 2025 Sep;26(9):1240-1251. doi: 10.1016/S1470-2045(25)00352-3. Epub 2025 Aug 11. PubMed 40812325
- Salvatore L, Fakih M, Kuboki Y, Hong DS, Modest DP, Taieb J, Price TJ, Cremolini C, Majer IM, Rehn M, Chan E, Chen Z, Tran Q, Pietrantonio F. Matching-Adjusted Indirect Comparison of Sotorasib Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Chemorefractory Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2026 Apr 23:S1533-0028(26)00026-5. doi: 10.1016/j.clcc.2026.04.003. Online ahead of print. PubMed 42173791